drug trial for people with secondary progressive MS
EDMONTON, Alberta, Canada
BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company’s pivotal phase II/III MAESTRO-01 trial of MBP8298 in patients with secondary progressive MS has completed a planned interim safety analysis and recommended that the trial continue as per the protocol.
